|
Author Archive: AZBio
Arizona Innovation Challenge – Fall 2018
There are THREE upcoming workshops next week where ACA will talk about the competition updates first, for all interested stakeholders (about 20 minutes), and then for the remainder of the session, for applicant companies, will be our traditional interactive track on more details about the application/contest process and how to submit a more competitive application. See details and register for these workshops online, here. The main workshop info is as follows: Monday, 8/27 – Phoenix (at ACA) – 3 to 5 PM; Wednesday, 8/29 – Phoenix (at ACA) – 8 to 10 AM; and Friday, 8/31 – Tucson (at Connect Coworking) – 8 to 10 AM. All the workshops are FREE.Continue reading
Arizona Bioscience Community Honors Brigadier General Ronald E. Shoopman (USAF Retired) with the 2018 AZBio Award for Public Service
CHANDLER, Ariz — (BUSINESS WIRE) — The Arizona Bioindustry Association (AZBio) today announced that Brigadier General Ronald E. Shoopman (USAF Retired), Chairman of the Arizona Board of Regents is the recipient of the 2018 AZBio Award for Public Service. Shoopman will be honored by Arizona’s bioscience and business communities for his leadership and service to the people of Arizona at the 2018 AZBio Awards on October 3, 2018 at the Phoenix Convention Center.Continue reading
Legal Lunch – Inter Partes Review
The inter partes review process for challenging the validity of patents at the U.S. Patent Office
This presentation was recorded on August 14, 2018 as part of the Legal Lunch series hosted for AZBio by Perkins Coie.Continue reading
NASA Awards a $127,000 STTR Research Grant to PADT and ASU for Advanced Research in 3D Printing
The Grant Represents the Strength of 3D Printing in Arizona Exemplified by the Strong Cooperation Between Industry and AcademiaContinue reading
Cancer Prevention Pharmaceuticals Completes North American Licensing Deal with Mallinckrodt
- License includes 50/50 profit share and additional payments of up to $185 million dependent on achieving clinical development and sales milestones, and subject to certain reductions
- Phase 3 clinical trial results for CPP-1X/sul in patients with Familial Adenomatous Polyposis expected in 1H 2019